Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.68 |
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135431 | 0.81 | UTS2R (1.00) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8343374 | 0.81 | UTS2R (0.66) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6135427 | 0.79 | UTS2R (0.67) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6135388 | 0.76 | PFKFB4 (0.44) | UTS2RMEN1KMT2AALOX15MAPK1 | |
| SCHEMBL8337845 | 0.76 | UTS2R (0.59) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5835169 | 0.75 | UTS2R (1.00) | UTS2R | |
| SCHEMBL5835165 | 0.75 | UTS2R (1.00) | UTS2R | |
| SCHEMBL6815276 | 0.75 | UTS2R (0.71) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6815264 | 0.75 | UTS2R (0.71) | UTS2RAXLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8294765 | 0.75 | UTS2R (1.00) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385495-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | claimed |
| EP-1385495-A2 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002089740-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1385495-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1385495-A2 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089740-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | UTS2R, SPINT2, PRSS2 | UTS2R 1/4885AXL 485/4885SMN1; SMN2 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.